Cartography Biosciences to Participate in Upcoming Investor Conferences
Cartography Biosciences to Participate in Upcoming Investor Conferences
Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that CEO and co-founder Kevin Parker, Ph.D., will participate in the following upcoming investor conferences:
- BofA Healthcare Trailblazers Private Company Conference: September 23-24 in Boston
- Needham Private Biotech and MedTech Company Virtual 1×1 Forum: October 13-14
- Goldman Sachs Healthcare Private Company Conference: October 19 in New York City
- Leerink Partners Biopharma Private Company Connect: October 20-21
- UBS Global Biopharma Conference: November 16-17 in London
About Cartography Biosciences
Cartography Biosciences is advancing a differentiated oncology pipeline of antibody-based therapies designed to target tumors with unprecedented precision. The company’s ATLAS and SUMMIT discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across healthy tissues alongside large-scale single-cell profiling of patient tumors. By combining petabyte-scale proprietary data, machine learning, and AI-driven biological insights, Cartography is identifying highly specific tumor targets and logic-gated target combinations to generate therapies engineered for maximal tumor selectivity and meaningful patient impact. The company’s lead program, CBI-1214, is a T-cell engager in development for colorectal cancer. CBI-1214 entered the clinic in early 2026 and is currently enrolling and treating patients in a phase 1 trial.
Media Contacts
Cartography Biosciences
Ashlea Kosikowski
ashlea@1abmedia.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260922998191/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
Christine Benz: Why I Hired a Financial Planner
United States